Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 63
Filter
1.
J Enzyme Inhib Med Chem ; 39(1): 2287420, 2024 Dec.
Article in English | MEDLINE | ID: mdl-38058285

ABSTRACT

The phytochemical investigation of the methanol extract of the seeds of Magydaris pastinacea afforded two undescribed benzofuran glycosides, furomagydarins A-B (1, 2), together with three known coumarins. The structures of the new isolates were elucidated after extensive 1D and 2D NMR experiments as well as HR MS. Compound 1 was able to inhibit the COX-2 expression in RAW264.7 macrophages exposed to lipopolysaccharide, a pro-inflammatory stimulus. RT-qPCR and luciferase reporter assays suggested that compound 1 reduces COX-2 expression at the transcriptional level. Further studies highlighted the capability of compound 1 to suppress the LPS-induced p38MAPK, JNK, and C/EBPß phosphorylation, leading to COX-2 down-regulation in RAW264.7 macrophages.


Subject(s)
Benzofurans , Glycosides , Benzofurans/pharmacology , CCAAT-Enhancer-Binding Protein-beta/metabolism , Cyclooxygenase 2/metabolism , Glycosides/pharmacology , Lipopolysaccharides/pharmacology , NF-kappa B/metabolism , Phosphorylation , p38 Mitogen-Activated Protein Kinases/metabolism , MAP Kinase Kinase 4/metabolism , Magnoliopsida/chemistry
2.
J Enzyme Inhib Med Chem ; 38(1): 2270183, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37870190

ABSTRACT

Tumour associated carbonic anhydrases (CAs) IX and XII have been recognised as potential targets for the treatment of hypoxic tumours. Therefore, considering the high pharmacological potential of the chromene scaffold as selective ligand of the IX and XII isoforms, two libraries of compounds, namely 2H-chromene and 7H-furo-chromene derivatives, with diverse substitution patterns were designed and synthesised. The structure of the newly synthesised compounds was characterised and their inhibitory potency and selectivity towards human CA off target isoforms I, II and cancer-associated CA isoforms IX and XII were evaluated. Most of the compounds inhibit CA isoforms IX and XII with no activity against the I and II isozymes. Thus, while the potency was influenced by the substitution pattern along the chromene scaffold, the selectivity was conserved along the series, confirming the high potential of both 2H-chromene and 7H-furo-chromene scaffolds for the design of isozyme selective inhibitors.


Subject(s)
Carbonic Anhydrases , Neoplasms , Humans , Carbonic Anhydrase IX , Carbonic Anhydrases/metabolism , Carbonic Anhydrase I , Carbonic Anhydrase II , Structure-Activity Relationship , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrase Inhibitors/chemistry , Neoplasms/drug therapy , Neoplasms/pathology , Antigens, Neoplasm/chemistry , Benzopyrans/pharmacology , Isoenzymes/metabolism , Molecular Structure
3.
Front Cell Infect Microbiol ; 13: 1193280, 2023.
Article in English | MEDLINE | ID: mdl-37424782

ABSTRACT

In the effort to identify and develop new HIV-1 inhibitors endowed with innovative mechanisms, we focused our attention on the possibility to target more than one viral encoded enzymatic function with a single molecule. In this respect, we have previously identified by virtual screening a new indolinone-based scaffold for dual allosteric inhibitors targeting both reverse transcriptase-associated functions: polymerase and RNase H. Pursuing with the structural optimization of these dual inhibitors, we synthesized a series of 35 new 3-[2-(4-aryl-1,3-thiazol-2-ylidene)hydrazin-1-ylidene]1-indol-2-one and 3-[3-methyl-4-arylthiazol-2-ylidene)hydrazine-1-ylidene)indolin-2-one derivatives, which maintain their dual inhibitory activity in the low micromolar range. Interestingly, compounds 1a, 3a, 10a, and 9b are able to block HIV-1 replication with EC50 < 20 µM. Mechanism of action studies showed that such compounds could block HIV-1 integrase. In particular, compound 10a is the most promising for further multitarget compound development.


Subject(s)
HIV-1 , Reverse Transcriptase Inhibitors , Reverse Transcriptase Inhibitors/chemistry , Reverse Transcriptase Inhibitors/pharmacology , Structure-Activity Relationship , Oxindoles , HIV Reverse Transcriptase/chemistry , HIV Reverse Transcriptase/metabolism , Virus Replication
4.
Int J Mol Sci ; 24(6)2023 Mar 12.
Article in English | MEDLINE | ID: mdl-36982496

ABSTRACT

Pancreatic cancer remains one of the deadliest cancer types. It is usually characterized by high resistance to chemotherapy. However, cancer-targeted drugs, such as sunitinib, recently have shown beneficial effects in pancreatic in vitro and in vivo models. Therefore, we chose to study a series of sunitinib derivatives developed by us, that were proven to be promising compounds for cancer treatment. The aim of our research was to evaluate the anticancer activity of sunitinib derivatives in human pancreatic cancer cell lines MIA PaCa-2 and PANC-1 under normoxia and hypoxia. The effect on cell viability was determined by the MTT assay. The compound effect on cell colony formation and growth was established by clonogenic assay and the activity on cell migration was estimated using a 'wound healing' assay. Six out of 17 tested compounds at 1 µM after 72 h of incubation reduced cell viability by 90% and were more active than sunitinib. Compounds for more detailed experiments were chosen based on their activity and selectivity towards cancer cells compared to fibroblasts. The most promising compound EMAC4001 was 24 and 35 times more active than sunitinib against MIA PaCa-2 cells, and 36 to 47 times more active against the PANC-1 cell line in normoxia and hypoxia. It also inhibited MIA PaCa-2 and PANC-1 cell colony formation. Four tested compounds inhibited MIA PaCa-2 and PANC-1 cell migration under hypoxia, but none was more active than sunitinib. In conclusion, sunitinib derivatives possess anticancer activity in human pancreatic adenocarcinoma MIA PaCa-2 and PANC-1 cell lines, and they are promising for further research.


Subject(s)
Adenocarcinoma , Antineoplastic Agents , Pancreatic Neoplasms , Humans , Sunitinib/pharmacology , Sunitinib/therapeutic use , Pancreatic Neoplasms/pathology , Adenocarcinoma/drug therapy , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Cell Culture Techniques , Hypoxia/drug therapy , Cell Line, Tumor , Cell Proliferation , Pancreatic Neoplasms
5.
Bioorg Chem ; 128: 106071, 2022 11.
Article in English | MEDLINE | ID: mdl-35932498

ABSTRACT

The Bcr-Abl tyrosine kinase (TK) is the molecular hallmark of chronic myeloid leukemia (CML). Src is another TK kinase whose involvement in CML was widely demonstrated. Small molecules active as dual Src/Bcr-Abl inhibitors emerged as effective targeted therapies for CML and a few compounds are currently in clinical use. In this study, we applied a target-oriented approach to identify a family of pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl inhibitors as anti-leukemia agents. Considering the high homology between Src and Bcr-Abl, in-house Src inhibitors 8a-l and new analogue compounds 9a-n were screened as dual Src/Bcr-Abl inhibitors. The antiproliferative activity on K562 CML cells and the ADME profile were determined for the most promising compounds. Molecular modeling studies elucidated the binding mode of the inhibitors into the Bcr-Abl (wt) catalytic pocket. Compounds 8j and 8k showed nanomolar activities in enzymatic and cellular assays, together with favorable ADME properties, emerging as promising candidates for CML therapy. Finally, derivatives 9j and 9k, emerging as valuable inhibitors of the most aggressive Bcr-Abl mutation, T315I, constitute a good starting point in the search for compounds able to treat drug-resistant forms of CML. Overall, this study allowed us to identify more potent compounds than those previously reported by the group, marking a step forward in searching for new antileukemic agents.


Subject(s)
Antineoplastic Agents , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Benzamides/therapeutic use , Drug Resistance, Neoplasm , Fusion Proteins, bcr-abl , Humans , Imatinib Mesylate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Piperazines/pharmacology , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/therapeutic use , Pyrimidines/chemistry
6.
Psychopharmacology (Berl) ; 239(3): 795-806, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35088095

ABSTRACT

BACKGROUND: Docosanyl ferulate (DF) is a behaviourally active GABAA receptor complex (GABAAR) agonist, recently isolated from the standardized methanolic extract of Withania somnifera Dunal (WSE) root. Previous studies have shown that WSE prevents both ethanol- and morphine-dependent acquisition and expression of conditioned place preference (CPP) and stimulation of dopamine release in the nucleus accumbens shell (AcbSh). AIMS: The study aimed at determining (a) whether DF contributes to WSE's ability to affect the acquisition and expression of ethanol- and morphine-elicited CPP and, given that phosphorylation of extracellular signal-regulated kinase (pERK) in the AcbSh is involved in associative learning and motivated behaviours, (b) whether WSE and DF may affect ethanol- and morphine-induced ERKs phosphorylation in the AcbSh. METHODS: In adult male CD1 mice, DF's effects on the acquisition and expression of ethanol- and morphine-elicited CPP were evaluated by a classical place conditioning paradigm, whereas the effects of WSE and DF on ethanol- and morphine-elicited pERK in the AcbSh were evaluated by immunohistochemistry. RESULTS AND CONCLUSIONS: The study shows that DF, differently from WSE, affects only the acquisition but not the expression of ethanol- and morphine-induced CPP. Moreover, the study shows that both WSE and DF can prevent ethanol- and morphine-elicited pERK expression in the AcbSh. Overall, these results highlight subtle but critical differences for the role of GABAARs in the mechanism by which WSE affects these ethanol- and morphine-dependent behavioural and molecular/cellular responses and support the suggestion of WSE and DF for the control of different components of drug addiction.


Subject(s)
Withania , Animals , Ethanol/pharmacology , Mice , Morphine/pharmacology , Nucleus Accumbens , Phosphorylation , Plant Extracts/pharmacology
7.
Molecules ; 26(13)2021 Jun 23.
Article in English | MEDLINE | ID: mdl-34201561

ABSTRACT

Current therapeutic protocols for the treatment of HIV infection consist of the combination of diverse anti-retroviral drugs in order to reduce the selection of resistant mutants and to allow for the use of lower doses of each single agent to reduce toxicity. However, avoiding drugs interactions and patient compliance are issues not fully accomplished so far. Pursuing on our investigation on potential anti HIV multi-target agents we have designed and synthesized a small library of biphenylhydrazo 4-arylthiazoles derivatives and evaluated to investigate the ability of the new derivatives to simultaneously inhibit both associated functions of HIV reverse transcriptase. All compounds were active towards the two functions, although at different concentrations. The substitution pattern on the biphenyl moiety appears relevant to determine the activity. In particular, compound 2-{3-[(2-{4-[4-(hydroxynitroso)phenyl]-1,3-thiazol-2-yl} hydrazin-1-ylidene) methyl]-4-methoxyphenyl} benzamide bromide (EMAC2063) was the most potent towards RNaseH (IC50 = 4.5 mM)- and RDDP (IC50 = 8.0 mM) HIV RT-associated functions.


Subject(s)
Anti-HIV Agents/chemistry , HIV Reverse Transcriptase/antagonists & inhibitors , HIV-1/metabolism , Ribonuclease H/antagonists & inhibitors , Thiazoles/chemistry , Thiazoles/pharmacology , Anti-HIV Agents/pharmacology , HIV Reverse Transcriptase/chemistry , HIV-1/enzymology , Inhibitory Concentration 50 , Ligands , Molecular Docking Simulation , Small Molecule Libraries , Structure-Activity Relationship , Thiazoles/chemical synthesis
8.
J Psychopharmacol ; 35(10): 1277-1284, 2021 Oct.
Article in English | MEDLINE | ID: mdl-33934670

ABSTRACT

BACKGROUND: Clinical and experimental studies support the therapeutic potential of Withania somnifera (WS) (L.) Dunal on anxiety disorders. This potential is attributable to components present in different plant extracts; however, the individual compound(s) endowed with specific anxiolytic effects and potential modulatory activity of the GABAA receptor complex (GABAAR) have remained unidentified until the recent isolation from a WS methanolic root extract of some GABAAR-active compounds, including the long alkyl-chain ferulic acid ester, docosanyl ferulate (DF). AIMS: This study was designed to assess whether DF (0.05, 0.25 and 2 mg/kg), similarly to diazepam (2 mg/kg), may exert anxiolytic effects, whether these effects may be significantly blocked by the benzodiazepine antagonist flumazenil (10 mg/kg) and whether DF may lack some of the benzodiazepines' typical motor, cognitive and motivational side effects. METHODS: The behavioural paradigms Elevated Plus Maze, Static Rods, Novel Object Recognition, Place Conditioning and potentiation of ethanol-induced Loss of Righting Reflex were applied on male CD-1 mice. RESULTS: Similarly to diazepam, DF exerts anxiolytic effects that are blocked by flumazenil. Moreover, at the full anxiolytic dose of 2 mg/kg, DF lacks typical benzodiazepine-like side effects on motor and cognitive performances and on place conditioning. Moreover, DF fails to potentiate ethanol's (3 g/kg) depressant activity at the ethanol-induced Loss of Righting Reflex paradigm. CONCLUSIONS: These data point to DF as an effective benzodiazepine-like anxiolytic compound that, in light of its lack of motor, mnemonic and motivational side effects, could be a suitable candidate for the treatment of anxiety disorders.


Subject(s)
Anti-Anxiety Agents , Plant Extracts , Withania , Animals , Male , Mice , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/pharmacology , Behavior, Animal/drug effects , Diazepam/pharmacology , Dose-Response Relationship, Drug , Ethanol/pharmacology , Flumazenil/pharmacology , Maze Learning/drug effects , Plant Extracts/administration & dosage , Plant Extracts/pharmacology , Reflex, Righting/drug effects , Withania/chemistry
9.
J Enzyme Inhib Med Chem ; 36(1): 749-757, 2021 Dec.
Article in English | MEDLINE | ID: mdl-33715562

ABSTRACT

Bioassay-guided fractionation of the ethyl acetate extract from Teucrium flavum subsp. glaucum, endowed with inhibitory activity towards the HIV-1 reverse transcriptase-associated RNase H function, led to the isolation of salvigenin (1), cirsimaritin (2) and cirsiliol (3) along with the neo-clerodanes teuflavin (4) and teuflavoside (5). Acid hydrolysis of the inactive teuflavoside provided three undescribed neo-clerodanes, flavuglaucins A-C (7-9) and one known neo-clerodane (10). Among all neo-clerodanes, flavuglaucin B showed the highest inhibitory activity towards RNase H function with a IC50 value of 9.1 µM. Molecular modelling and site-directed mutagenesis analysis suggested that flavuglaucin B binds into an allosteric pocket close to RNase H catalytic site. This is the first report of clerodane diterpenoids endowed with anti-reverse transcriptase activity. Neo-clerodanes represent a valid scaffold for the development of a new class of HIV-1 RNase H inhibitors.


Subject(s)
Diterpenes, Clerodane/pharmacology , Flavonoids/pharmacology , HIV Reverse Transcriptase/antagonists & inhibitors , Plant Extracts/pharmacology , Reverse Transcriptase Inhibitors/pharmacology , Ribonuclease H/antagonists & inhibitors , Teucrium/chemistry , Diterpenes, Clerodane/chemistry , Diterpenes, Clerodane/isolation & purification , Dose-Response Relationship, Drug , Flavonoids/chemistry , Flavonoids/isolation & purification , HIV Reverse Transcriptase/genetics , HIV Reverse Transcriptase/metabolism , Hydrogen-Ion Concentration , Hydrolysis , Models, Molecular , Molecular Conformation , Mutagenesis, Site-Directed , Plant Extracts/chemistry , Plant Extracts/isolation & purification , Reverse Transcriptase Inhibitors/chemistry , Reverse Transcriptase Inhibitors/isolation & purification , Ribonuclease H/genetics , Ribonuclease H/metabolism , Structure-Activity Relationship
10.
J Enzyme Inhib Med Chem ; 36(1): 685-692, 2021 Dec.
Article in English | MEDLINE | ID: mdl-33602041

ABSTRACT

A small library of coumarin and their psoralen analogues EMAC10157a-b-d-g and EMAC10160a-b-d-g has been designed and synthesised to investigate the effect of structural modifications on their inhibition ability and selectivity profile towards carbonic anhydrase isoforms I, II, IX, and XII. None of the new compounds exhibited activity towards hCA I and II isozymes. Conversely, both coumarin and psoralen derivatives were active against tumour associated isoforms IX and XII in the low micromolar or nanomolar range of concentration. These data further corroborate our previous findings on analogous derivatives, confirming that both coumarins and psoralens are interesting scaffolds for the design of isozyme selective hCA inhibitors.


Subject(s)
Carbonic Anhydrase IX/antagonists & inhibitors , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrases/metabolism , Coumarins/pharmacology , Ficusin/pharmacology , Antigens, Neoplasm/metabolism , Carbonic Anhydrase IX/metabolism , Carbonic Anhydrase Inhibitors/chemical synthesis , Carbonic Anhydrase Inhibitors/chemistry , Coumarins/chemical synthesis , Coumarins/chemistry , Dose-Response Relationship, Drug , Ficusin/chemical synthesis , Ficusin/chemistry , Humans , Models, Molecular , Molecular Structure , Structure-Activity Relationship
11.
Article in English | MEDLINE | ID: mdl-32366711

ABSTRACT

Ebola virus (EBOV) is among the most devastating pathogens causing fatal hemorrhagic fever in humans. The epidemics from 2013 to 2016 resulted in more than 11,000 deaths, and another outbreak is currently ongoing. Since there is no FDA-approved drug so far to fight EBOV infection, there is an urgent need to focus on drug discovery. Considering the tight correlation between the high EBOV virulence and its ability to suppress the type I interferon (IFN-I) system, identifying molecules targeting viral protein VP24, one of the main virulence determinants blocking the IFN response, is a promising novel anti-EBOV therapy approach. Hence, in the effort to find novel EBOV inhibitors, a screening of a small set of flavonoids was performed; it showed that quercetin and wogonin can suppress the VP24 effect on IFN-I signaling inhibition. The mechanism of action of the most active compound, quercetin, showing a half-maximal inhibitory concentration (IC50) of 7.4 µM, was characterized to significantly restore the IFN-I signaling cascade, blocked by VP24, by directly interfering with the VP24 binding to karyopherin-α and thus restoring P-STAT1 nuclear transport and IFN gene transcription. Quercetin significantly blocked viral infection, specifically targeting EBOV VP24 anti-IFN-I function. Overall, quercetin is the first identified inhibitor of the EBOV VP24 anti-IFN function, representing a molecule interacting with a viral binding site that is very promising for further drug development aiming to block EBOV infection at the early steps.


Subject(s)
Ebolavirus , Hemorrhagic Fever, Ebola , Interferons , Quercetin , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Ebolavirus/drug effects , Hemorrhagic Fever, Ebola/drug therapy , Humans , Quercetin/pharmacology , Viral Proteins/antagonists & inhibitors
12.
ACS Med Chem Lett ; 11(5): 852-856, 2020 May 14.
Article in English | MEDLINE | ID: mdl-32435395

ABSTRACT

In the present study we investigated the structure-activity relationships of a new series of 4-[(3-ethyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzene-1-sulfonamides (EMAC10101a-m). All synthesized compounds, with the exception of compound EMAC10101k, preferentially inhibit off-target hCA II isoform. Within the series, compound EMAC10101d, bearing a 2,4-dichorophenyl substituent in position 4 of the dihydrothiazole ring, was the most potent and selective toward hCA II with an inhibitory activity in the low nanomolar range.

13.
J Enzyme Inhib Med Chem ; 35(1): 539-548, 2020 Dec.
Article in English | MEDLINE | ID: mdl-31948300

ABSTRACT

In an in vitro screening for human carbonic anhydrase (hCA) inhibiting agents from higher plants, the petroleum ether and ethyl acetate extracts of Magydaris pastinacea seeds selectively inhibited hCA IX and hCA XII isoforms. The phytochemical investigation of the extracts led to the isolation of ten linear furocoumarins (1-10), four simple coumarins (12-15) and a new angular dihydrofurocoumarin (11). The structures of the isolated compounds were elucidated based on 1 D and 2 D NMR, MS, and ECD data analysis. All isolated compounds were inactive towards the ubiquitous cytosolic isoform hCA I and II (Ki > 10,000 nM) while they were significantly active against the tumour-associated isoforms hCA IX and XII. Umbelliprenin was the most potent coumarin inhibiting hCA XII isoform with a Ki of 5.7 nM. The cytotoxicity of the most interesting compounds on HeLa cancer cells was also investigated.


Subject(s)
Apiaceae/chemistry , Carbonic Anhydrase IX/antagonists & inhibitors , Carbonic Anhydrase Inhibitors/isolation & purification , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrases/metabolism , Computer Simulation , Coumarins/isolation & purification , Coumarins/pharmacology , Antigens, Neoplasm/metabolism , Carbonic Anhydrase IX/metabolism , Carbonic Anhydrase Inhibitors/chemistry , Coumarins/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Structure , Seeds/chemistry , Structure-Activity Relationship
14.
J Enzyme Inhib Med Chem ; 34(1): 1526-1533, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31431095

ABSTRACT

A library of 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzene-1-sulphonamides (EMAC8002a-m) was designed and synthesised to evaluate the effect of substituents in the positions 3 and 4 of the dihydrothiazole ring on the inhibitory potency and selectivity toward human carbonic anhydrase isoforms I, II, IX, and XII. Most of the new compounds preferentially inhibit the isoforms II and XII. Both electronic and steric features on the aryl substituent in the position 4 of the dihydrothiazole ring concur to determine the overall biological activity of these new derivatives.


Subject(s)
Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrases/metabolism , Carbonic Anhydrase Inhibitors/chemical synthesis , Carbonic Anhydrase Inhibitors/chemistry , Dose-Response Relationship, Drug , Humans , Isoenzymes/antagonists & inhibitors , Isoenzymes/metabolism , Models, Molecular , Molecular Structure , Structure-Activity Relationship
15.
Eur J Med Chem ; 182: 111617, 2019 Nov 15.
Article in English | MEDLINE | ID: mdl-31442684

ABSTRACT

A number of compounds targeting different processes of the Human Immunodeficiency Virus type 1 (HIV-1) life cycle have been developed in the continuing fight against AIDS. Coumarin-based molecules already proved to act as HIV-1 Protease (PR) or Integrase (IN) inhibitors and also to target HIV-1 reverse transcriptase (RT), blocking the DNA-dependent DNA-polymerase activity or the RNA-dependent DNA-polymerase activity working as common NNRTIs. In the present study, with the aim to exploit a coumarin-based scaffold to achieve the inhibition of multiple viral coded enzymatic functions, novel 4-hydroxy-2H, 5H-pyrano (3, 2-c) chromene-2, 5-dione derivatives were synthesized. The modeling studies calculated the theoretical binding affinity of the synthesized compounds on both HIV-1 IN and RT-associated Ribonuclease H (RNase H) active sites, which was confirmed by biological assays. Our results provide a basis for the identification of dual HIV-1 IN and RT RNase H inhibitors compounds.


Subject(s)
Anti-HIV Agents/pharmacology , Coumarins/pharmacology , HIV Integrase Inhibitors/pharmacology , HIV-1/drug effects , Reverse Transcriptase Inhibitors/pharmacology , Ribonuclease H, Human Immunodeficiency Virus/antagonists & inhibitors , Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/chemistry , Coumarins/chemical synthesis , Coumarins/chemistry , Dose-Response Relationship, Drug , HIV Integrase Inhibitors/chemical synthesis , HIV Integrase Inhibitors/chemistry , HIV-1/enzymology , Microbial Sensitivity Tests , Molecular Structure , Reverse Transcriptase Inhibitors/chemical synthesis , Reverse Transcriptase Inhibitors/chemistry , Ribonuclease H, Human Immunodeficiency Virus/metabolism , Structure-Activity Relationship
16.
J Nat Prod ; 82(5): 1250-1257, 2019 05 24.
Article in English | MEDLINE | ID: mdl-30998355

ABSTRACT

Nine compounds, including two undescribed withanolides, withasomniferolides A and B (1 and 2), three known withanolides (3-5), a ferulic acid dimeric ester (6), and an inseparable mixture of three long alkyl chain ferulic acid esters (7-9), were isolated from a GABAA receptor positive activator methanol extract of the roots of Withania somnifera. The structures of the isolated compounds were elucidated based on NMR, MS, and ECD data analysis. In order to bioassay the single ferulic acid derivatives, compounds 6-9 were also synthesized. The most active compound, docosanyl ferulate (9), was able to enhance the GABAA receptor inhibitory postsynaptic currents with an IC50 value of 7.9 µM. These results, by showing an ability to modulate the GABAA receptor function, cast fresh light on the biological activities of the secondary metabolites of W. somnifera roots.


Subject(s)
Coumaric Acids/pharmacology , GABA Modulators/pharmacology , Receptors, GABA-A/drug effects , Withania/chemistry , Withanolides/pharmacology , Animals , Coumaric Acids/chemical synthesis , Esters/chemical synthesis , Esters/pharmacology , GABA Modulators/chemical synthesis , In Vitro Techniques , Inhibitory Postsynaptic Potentials/drug effects , Magnetic Resonance Spectroscopy , Male , Molecular Structure , Plant Extracts/chemistry , Plant Roots/chemistry , Rats , Rats, Sprague-Dawley , Withanolides/chemical synthesis , Xenopus
17.
ACS Med Chem Lett ; 10(4): 571-576, 2019 Apr 11.
Article in English | MEDLINE | ID: mdl-30996798

ABSTRACT

A series of isatin-dihydropyrazole hybrids have been synthesized in order to assess their potential as anticancer agents. In particular, 12 compounds were evaluated for their antiproliferative activity toward A549, IGR39, U87, MDA-MB-231, MCF-7, BT474, BxPC-3, SKOV-3, and H1299 cell lines, and human foreskin fibroblasts. Four compounds exhibited interesting antiproliferative activity and were further examined to determine their EC50 values toward a panel of selected tumor cell lines. The best compounds were then investigated for their induced mechanism of cell death. Preliminary structure-activity relationship indicates that the presence of a substituent such as a chlorine atom or a methyl moiety in position 5 of the isatin nucleus is beneficial for the antitumor activity. EMAC4001 proved the most promising compound within the studied series with EC50 values ranging from 0.01 to 0.38 µM.

18.
Eur J Med Chem ; 161: 1-10, 2019 Jan 01.
Article in English | MEDLINE | ID: mdl-30342421

ABSTRACT

In this work we report a parallel application of both docking- and shape-based virtual screening (VS) methods, followed by Molecular Dynamics simulations (MDs), for discovering new compounds able to inhibit the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) RNA-dependent DNA polymerase activity. Specifically, we screened more than 143000 natural compounds commercially available in the ZINC database against the best five RT crystallographic models, taking into account the five approved NNRTIs as query compounds. As a result, 20 hit molecules were selected and tested on biochemical assays for the inhibition of the RNA dependent DNA polymerase RT function and, among them, an indoline pyrrolidine (hit1), an indonyl piperazine (hit2) and an indolyl indolinone (hit3) derivatives were identified as novel non-nucleoside RT inhibitors in the low micromolar range.


Subject(s)
Biological Products/pharmacology , HIV Reverse Transcriptase/antagonists & inhibitors , HIV-1/drug effects , Reverse Transcriptase Inhibitors/pharmacology , Biological Products/chemistry , Drug Evaluation, Preclinical , HIV Reverse Transcriptase/metabolism , HIV-1/enzymology , Humans , Microbial Sensitivity Tests , Molecular Conformation , Molecular Dynamics Simulation , Reverse Transcriptase Inhibitors/chemistry
19.
J Enzyme Inhib Med Chem ; 34(1): 55-74, 2019 Dec.
Article in English | MEDLINE | ID: mdl-30362381

ABSTRACT

The paper focussed on a step-by-step structural modification of a cycloheptathiophene-3-carboxamide derivative recently identified by us as reverse transcriptase (RT)-associated ribonuclease H (RNase H) inhibitor. In particular, its conversion to a 2-aryl-cycloheptathienoozaxinone derivative and the successive thorough exploration of both 2-aromatic and cycloheptathieno moieties led to identify oxazinone-based compounds as new anti-RNase H chemotypes. The presence of the catechol moiety at the C-2 position of the scaffold emerged as critical to achieve potent anti-RNase H activity, which also encompassed anti-RNA dependent DNA polymerase (RDDP) activity for the tricyclic derivatives. Benzothienooxazinone derivative 22 resulted the most potent dual inhibitor exhibiting IC50s of 0.53 and 2.90 µM against the RNase H and RDDP functions. Mutagenesis and docking studies suggested that compound 22 binds two allosteric pockets within the RT, one located between the RNase H active site and the primer grip region and the other close to the DNA polymerase catalytic centre.


Subject(s)
Anti-HIV Agents/pharmacology , HIV/drug effects , Oxazines/pharmacology , Reverse Transcriptase Inhibitors/pharmacology , Ribonuclease H, Human Immunodeficiency Virus/antagonists & inhibitors , Thiophenes/pharmacology , Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/chemistry , Cell Line , Dose-Response Relationship, Drug , HIV/metabolism , Humans , Molecular Docking Simulation , Molecular Structure , Oxazines/chemical synthesis , Oxazines/chemistry , Reverse Transcriptase Inhibitors/chemical synthesis , Reverse Transcriptase Inhibitors/chemistry , Ribonuclease H, Human Immunodeficiency Virus/metabolism , Structure-Activity Relationship , Thiophenes/chemical synthesis , Thiophenes/chemistry
20.
Antiviral Res ; 162: 110-117, 2019 02.
Article in English | MEDLINE | ID: mdl-30586561

ABSTRACT

The 4th Summer School on Innovative Approaches for the Identification of Antiviral Agents (IAAASS) was held at the Sardegna Ricerche Research Park in Santa Margherita di Pula, Sardinia, Italy from September 24-28, 2018. The Summer School assembled 21 internationally recognized experts and 46 graduate and postgraduate students, with the goal of discussing advances in antiviral drug discovery from the perspective of high-throughput screening, medicinal chemistry, computational chemistry, virology, molecular and structural biology. The meeting format involved three components: (a) morning sessions of plenary talks/overviews from invited speakers, (b) afternoon sessions of posters and short presentations from student participants, and (c) informal small-group discussions between students and participating faculty. Plenary talks also featured a roundtable discussion of the pros and cons of moving into an academic career versus employment in the pharmaceutical industry, featuring individuals with experience in one or both arenas. The success of the IAAASS has come from placing emphasis on informal interactions, through which speakers made themselves available to students throughout the Summer School. This report provides a summary of scientific contributions presented by the lecturers at the 4th IAAASS, with enclosed a supplementary file containing the abstracts of selected oral presentations and poster presentations.


Subject(s)
Antiviral Agents/chemistry , Antiviral Agents/isolation & purification , Drug Discovery/methods , Chemistry, Pharmaceutical , Computers, Molecular , Congresses as Topic , High-Throughput Screening Assays , Humans , Italy
SELECTION OF CITATIONS
SEARCH DETAIL
...